Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial

Conclusions Budesonide at a mean dose of 4.5 mg/day maintained clinical remission for at least 1 year in the majority of patients with collagenous colitis and preserved health-related quality of life without safety concerns. Treatment extension with low-dose budesonide beyond 1 year may be beneficial given the high relapse rate after budesonide discontinuation. Trial registration numbers http://www.clinicaltrials.gov (NCT01278082) and http://www.clinicaltrialsregister.eu (EudraCT: 2007-001315-31).

http://gut.bmj.com/cgi/content/short/65/1/47?rss=1

Source: Gut - December 8, 2015 Category: Gastroenterology Authors: Münch, A., Bohr, J., Miehlke, S., Benoni, C., Olesen, M., Öst, A., Strandberg, L., Hellström, P. M., Hertervig, E., Armerding, P., Stehlik, J., Lindberg, G., Björk, J., Lapidus, A., Löfberg, R., Bonderup, O., Avnstr Tags: Open access Inflammatory bowel disease Source Type: research

More News: Drugs & Pharmacology | Gastroenterology | Health | Inflammatory Bowel Disease | Study